Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Tian M, et al. Among authors: kim yy. Cell Rep Med. 2023 Oct 17;4(10):101212. doi: 10.1016/j.xcrm.2023.101212. Epub 2023 Sep 28. Cell Rep Med. 2023. PMID: 37774704 Free PMC article.
An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma.
Tian M, Cheuk AT, Wei JS, Abdelmaksoud A, Chou HC, Milewski D, Kelly MC, Song YK, Dower CM, Li N, Qin H, Kim YY, Wu JT, Wen X, Benzaoui M, Masih KE, Wu X, Zhang Z, Badr S, Taylor N, Croix BS, Ho M, Khan J. Tian M, et al. Among authors: kim yy. J Clin Invest. 2022 Aug 15;132(16):e155621. doi: 10.1172/JCI155621. J Clin Invest. 2022. PMID: 35852863 Free PMC article.
A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia.
Masih KE, Gardner RA, Chou HC, Abdelmaksoud A, Song YK, Mariani L, Gangalapudi V, Gryder BE, Wilson AL, Adebola SO, Stanton BZ, Wang C, Milewski D, Kim YY, Tian M, Cheuk AT, Wen X, Zhang Y, Altan-Bonnet G, Kelly MC, Wei JS, Bulyk ML, Jensen MC, Orentas RJ, Khan J. Masih KE, et al. Among authors: kim yy. Blood Adv. 2023 Aug 8;7(15):4218-4232. doi: 10.1182/bloodadvances.2022008977. Blood Adv. 2023. PMID: 36607839 Free PMC article.
Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
Wu JT, Cheuk A, Isanogle K, Robinson C, Zhang X, Ceribelli M, Beck E, Shinn P, Klumpp-Thomas C, Wilson KM, McKnight C, Itkin Z, Sotome H, Hirai H, Calleja E, Wacheck V, Gouker B, Peer CJ, Corvalan N, Milewski D, Kim YY, Figg WD, Edmondson EF, Thomas CJ, Difilippantonio S, Wei JS, Khan J. Wu JT, et al. Among authors: kim yy. Cancers (Basel). 2023 Aug 9;15(16):4034. doi: 10.3390/cancers15164034. Cancers (Basel). 2023. PMID: 37627061 Free PMC article.
KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY, Gryder BE, Sinniah R, Peach ML, Shern JF, Abdelmaksoud A, Pomella S, Woldemichael GM, Stanton BZ, Milewski D, Barchi JJ Jr, Schneekloth JS Jr, Chari R, Kowalczyk JT, Shenoy SR, Evans JR, Song YK, Wang C, Wen X, Chou HC, Gangalapudi V, Esposito D, Jones J, Procter L, O'Neill M, Jenkins LM, Tarasova NI, Wei JS, McMahon JB, O'Keefe BR, Hawley RG, Khan J. Kim YY, et al. Nat Commun. 2024 Feb 24;15(1):1703. doi: 10.1038/s41467-024-45902-y. Nat Commun. 2024. PMID: 38402212 Free PMC article.
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
Tian M, Wei JS, Shivaprasad N, Highfill SL, Gryder BE, Milewski D, Brown GT, Moses L, Song H, Wu JT, Azorsa P, Kumar J, Schneider D, Chou HC, Song YK, Rahmy A, Masih KE, Kim YY, Belyea B, Linardic CM, Dropulic B, Sullivan PM, Sorensen PH, Dimitrov DS, Maris JM, Mackall CL, Orentas RJ, Cheuk AT, Khan J. Tian M, et al. Among authors: kim yy. Cell Rep Med. 2024 May 21;5(5):101586. doi: 10.1016/j.xcrm.2024.101586. Epub 2024 May 9. Cell Rep Med. 2024. PMID: 38723625 Free PMC article. No abstract available.
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi J. Ohguchi H, et al. Blood Cancer Discov. 2021 Jul;2(4):370-387. doi: 10.1158/2643-3230.BCD-20-0108. Epub 2021 Apr 10. Blood Cancer Discov. 2021. PMID: 34258103 Free PMC article.
Do Risk Factors for HCC Impact the Association of CT/MRI LIRADS Major Features With HCC? An Individual Participant Data Meta-Analysis.
Adamo RG, Lam E, Salameh JP, van der Pol CB, Goins SM, Dawit H, Costa AF, Levis B, Singal AG, Chernyak V, Sirlin CB, Bashir MR, Tang A, Alhasan A, Allen BC, Reiner CS, Clarke C, Ludwig DR, Cerny M, Wang J, Hyun Choi S, Fraum TJ, Song B, Joo I, Yeon Kim S, Kwon H, Jiang H, Kang HJ, Kierans AS, Kim YY, Ronot M, Podgórska J, Rosiak G, Soo Song J, McInnes MDF. Adamo RG, et al. Among authors: kim yy. Can Assoc Radiol J. 2024 Dec 29:8465371241306297. doi: 10.1177/08465371241306297. Online ahead of print. Can Assoc Radiol J. 2024. PMID: 39733353
1,155 results